Edmond de Rothschild Private Equity logo

Edmond de Rothschild Private Equity

Europe, Ile-de-France, France, Paris

Description

Edmond de Rothschild Private Equity, a prominent division of the global Edmond de Rothschild Group, is a leading player in the European private equity landscape, headquartered in Paris, France. The firm specializes in managing and advising on investments in unlisted assets, focusing on long-term value creation across various strategies. Their approach emphasizes active partnership with management teams to foster growth and transformation in portfolio companies.

The private equity arm boasts significant scale, managing over €12 billion (approximately $13 billion USD) in assets under management as of early 2024. This capital is deployed across a diverse range of strategies, including growth capital, buyouts, infrastructure debt, and life sciences. Their investment philosophy is rooted in deep sector expertise and a commitment to responsible investment, integrating ESG factors into their decision-making processes to ensure sustainable value creation.

A key part of their equity strategy is exemplified by their Winch Capital funds, which target growth equity investments in French and European small and medium-sized enterprises (SMEs). For these growth-oriented equity deals, Edmond de Rothschild Private Equity typically provides initial equity tickets ranging from €15 million to €50 million (approximately $16.2 million to $54 million USD). Since its inception, the private equity business line has invested in over 100 companies, demonstrating a robust track record of supporting businesses through various stages of development and expansion.

Investor Profile

Edmond de Rothschild Private Equity has backed more than 20 startups, with 2 new investments in the last 12 months alone. The firm has led 5 rounds, about 25% of its total and boasts 8 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series C, Series A rounds (top funding stages).
  • Majority of deals are located in Switzerland, France, Germany.
  • Strong thematic focus on Biotechnology, Pharmaceutical, Health Care.
  • Typical check size: $16.2M – $54M.

Stage Focus

  • Series B (20%)
  • Series C (15%)
  • Series A (15%)
  • Private Equity (15%)
  • Series Unknown (10%)
  • Debt Financing (10%)
  • Post Ipo Debt (10%)
  • Post Ipo Equity (5%)

Country Focus

  • Switzerland (25%)
  • France (25%)
  • Germany (15%)
  • United States (15%)
  • United Kingdom (10%)
  • The Netherlands (5%)
  • Italy (5%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Biopharma
  • Medical
  • Therapeutics
  • Manufacturing
  • Internet
  • Energy
  • Energy Management
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Edmond de Rothschild Private Equity frequently co-invest with?

LSP BioVentures
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Ascent Biomedical Ventures
North America, New York, United States, New York
Co-Investments: 1
Bio*One Capital
Asia, Central Region, Singapore, Singapore
Co-Investments: 1
Index Ventures
North America, California, United States, San Francisco
Co-Investments: 3
Forbion Capital Partners
Europe, Noord-Holland, The Netherlands, Naarden
Co-Investments: 3
Atlas Venture
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Andera Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 7
Alta Partners
North America, Mississippi, United States, Jackson
Co-Investments: 1
EMBL Ventures
Europe, Baden-Wurttemberg, Germany, Heidelberg
Co-Investments: 2
Baxter Ventures
North America, Illinois, United States, Deerfield
Co-Investments: 1

Which angels does Edmond de Rothschild Private Equity often collaborate with?

NB
Europe, Basel-Stadt, Switzerland, Basel
Shared Deals: 1

What are some of recent deals done by Edmond de Rothschild Private Equity?

Hippocrates

Milan, Lombardia, Italy

Hippocrates is an Italian independent pharmacy platform with a network of over 120 owned pharmacies.

BeautyHealth CareInformation TechnologyInternetMedicalPharmaceutical
Debt FinancingMar 21, 2025
Amount Raised: $380,683,054
BE WTR

Lausanne, Vaud, Switzerland

BE WTR makes a variety of hygienic water taps for offices and other businesses.

Food and BeverageResidentialWaterWater Purification
Series COct 7, 2024
Amount Raised: $45,637,521
Oncodesign Services

Dijon, Bourgogne, France

Oncodesign Services specializes in drug discovery and preclinical services.

BiotechnologyMedical
Private EquityJan 23, 2024
Amount Raised: $23,886,612
Voltalis

Paris, Ile-de-France, France

Voltalis is an aggregation platform that connected energy saving solutions.

InternetSoftware
Private EquityMar 6, 2023
Amount Raised: $97,247,573
North Star

Aberdeen, Aberdeen City, United Kingdom

North Star is an operator of specialised vessels that offer emergency response and rescue and essential offshore wind maintenance services.

Marine TechnologyService Industry
Debt FinancingDec 6, 2022
Amount Raised: $169,858,181
Française de l'Energie

Forbach, Lorraine, France

Française de l'Energie engages in the exploration and evaluation of gas resources in France.

EnergyEnergy ManagementMiningOil and Gas
Post Ipo DebtOct 3, 2022
Amount Raised: $19,667,172
Française de l'Energie

Forbach, Lorraine, France

Française de l'Energie engages in the exploration and evaluation of gas resources in France.

EnergyEnergy ManagementMiningOil and Gas
Post Ipo DebtSep 27, 2021
Amount Raised: $46,784,118
Swiss Summit Capital

London, England, United Kingdom

Swiss Summit Capital uses a pattern recognition algorithm to provide timely stock market opportunities to your inbox.

Financial Services
Series AApr 5, 2019
Amount Raised: $23,698,223
Philogeris Group

Paris, Idaho, United States

Philogeris is a operating accommodation facility for dependent elderly people.

FitnessHealth CareWellness
Series UnknownOct 1, 2017
Complexa

Pittsburgh, Pennsylvania, United States

Complexa, a biopharmaceutical company, develops therapies for the treatment of inflammatory, and metabolic diseases.

BiotechnologyHealth CareTherapeutics
Series CJul 26, 2017
Amount Raised: $62,000,000